fda semaglutide warning november 2025 Approves for New Indication Involving Cardiovascular Disease FBI issues safety warning about

Summary: Saxenda may fail to suppress appetite or cause increased hunger due to insufficient dosing, incorrect injection technique, medication storage issues, dietary composition, psychological factors, underlying medical conditions, or inadequate sleep

(Ozempic, Wegovy): ( GLP-1)

Its a simple, credible choice for UK patients who want structure and safety over extra features

The 90-day money-back guarantee reduces financial risk for those who want to evaluate whether the product provides subjective benefits for their individual situation

Its second liraglutide formulation, Saxenda , was FDA-approved for weight loss in 2014